Abstract
VP-16-213 is a semisynthetic podophyllotoxin derivative which has been observed to have considerable activity against small cell undifferentiated lung cancer. Based on that encouraging clinical finding and the fact that the drug in the oral form has shown some activity against adenocarcinoma (ACA) of the lung as well, we elected to further evaluate the drug in patients with advanced squamous cell carcinoma (SQC) and ACA of the lung. VP-16-213 is a relatively well-tolerated chemotherapeutic agent when used in the manner described in this study. Definite antitumor activity was demonstrated in patients with both ACA and SQC of the lung. The overall regression rate of 18% (eight of 44 patients) when both ACA and SQC patients were combined, puts the drug in the same activity range as most single agents considered to have some effect in ACA and SQC of the lung such as cyclophosphamide and adriamycin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 843-844 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 62 |
| Issue number | 5 |
| State | Published - 1978 |
ASJC Scopus subject areas
- Oncology
- Cancer Research